Editas Medicine Inc expected to post a loss of 36 cents a share - Earnings Preview

Editas Medicine

24/02/2025 13:53

* Editas Medicine Inc  EDIT.OQ   EDIT.O  is expected to show
a
fall in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 46.3% decrease in revenue to $32.23 million from $60.05
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Editas Medicine Inc is
for a
loss of 36 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Editas
Medicine
Inc is $3.50​, above​ its last closing price of $1.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.72       -0.75      -0.75     Met     -0.4
 Jun. 30 2024  -0.73       -0.70      -0.82     Missed  -16.6
 Mar. 31 2024  -0.66       -0.66      -0.76     Missed  -14.3​
 Dec. 31 2023  -0.60       -0.54      -0.23     Beat    57.6
 ​​Sep.        -0.56       -0.57      -0.55     Beat    3.2
 30 2023                                                
 Jun. 30 2023  -0.76       -0.76      -0.56     Beat    26.6​
 Mar. 31 2023  -0.78       -0.78      -0.71     Beat    9.4
 Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7
 This summary was machine generated February 24 at 13:53 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)